Quick Answer
Definium Therapeutics, Inc. reported Operating Income of -$166.31 million for fiscal year 2025.
Definium Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$166.31M | -60.0% |
| 2024 | -$103.92M | -10.7% |
| 2023 | -$93.87M | -41.5% |
| 2022 | -$66.33M | +29.3% |
| 2021 | -$93.85M | -184.1% |
| 2020 | -$33.03M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$45.67M | -84.2% | -11.7% |
| June 30, 2025 | -$40.90M | -67.2% | -27.2% |
| March 31, 2025 | -$32.16M | -44.8% | -29.7% |
| September 30, 2024 | -$24.79M | -14.7% | -1.4% |
| June 30, 2024 | -$24.46M | +16.2% | -10.2% |
| March 31, 2024 | -$22.20M | -6.4% | -2.7% |
| September 30, 2023 | -$21.62M | -27.3% | +25.9% |
| June 30, 2023 | -$29.18M | -72.2% | -39.9% |
- Definium Therapeutics, Inc. showed a decrease of -60.0% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Definium Therapeutics, Inc.’s operating income has declined by 403.5% (from -$33.03 million to -$166.31 million).
- The most recent figure is from Definium Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: